Form 4: Dynavax Technologies CFO Kelly MacDonald Reports Stock Transactions

Sentiment:

SEC Form 4 Filing


Kelly MacDonald, SVP and CFO of Dynavax Technologies, reports the vesting of restricted stock units and subsequent stock transactions.

Summary

  • On February 10, 2025, Kelly MacDonald, the SVP and CFO of Dynavax Technologies, reported transactions involving Dynavax common stock.
  • MacDonald acquired 5,333 shares of common stock through the vesting of restricted stock units (RSUs).
  • Simultaneously, MacDonald disposed of 5,333 shares related to the vesting of these RSUs.
  • Additionally, 1,997 shares were disposed of to satisfy tax withholding requirements at a price of $13.2 per share.
  • Following these transactions, MacDonald directly owns 8,043 shares of Dynavax common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reflects routine stock transactions related to executive compensation.

Industry Context

Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be an indicator of management's confidence in the company's prospects.

Stakeholder Impact

  • The transactions have a minimal direct impact on stakeholders as they are part of standard executive compensation practices.

Key Dates

DateDescription
02/10/2022Initial vesting date for the restricted stock units, with 1/3 vesting annually.
02/10/2025Date of the reported stock transactions, including RSU vesting and tax withholding.
02/12/2025Date of signature for the Form 4 filing.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.